176 related articles for article (PubMed ID: 34144486)
1. Atorvastatin induces adrenal androgen downshift in men with prostate cancer: A post Hoc analysis of a pilot adaptive Randomised clinical trial.
Raittinen PVH; Syvälä H; Tammela TLJ; Häkkinen MR; Ilmonen P; Auriola S; Murtola TJ
EBioMedicine; 2021 Jun; 68():103432. PubMed ID: 34144486
[TBL] [Abstract][Full Text] [Related]
2. Atorvastatin Versus Placebo for Prostate Cancer Before Radical Prostatectomy-A Randomized, Double-blind, Placebo-controlled Clinical Trial.
Murtola TJ; Syvälä H; Tolonen T; Helminen M; Riikonen J; Koskimäki J; Pakarainen T; Kaipia A; Isotalo T; Kujala P; Tammela TLJ
Eur Urol; 2018 Dec; 74(6):697-701. PubMed ID: 30031572
[TBL] [Abstract][Full Text] [Related]
3. Randomised double-blind phase 3 clinical study testing impact of atorvastatin on prostate cancer progression after initiation of androgen deprivation therapy: study protocol.
Siltari A; Riikonen J; Koskimäki J; Pakarainen T; Ettala O; Boström P; Seikkula H; Kotsar A; Tammela T; Helminen M; Raittinen PV; Lehtimäki T; Fode M; Østergren P; Borre M; Rannikko A; Marttila T; Salonen A; Ronkainen H; Löffeler S; Murtola TJ
BMJ Open; 2022 Apr; 12(4):e050264. PubMed ID: 35487730
[TBL] [Abstract][Full Text] [Related]
4. Circulatory and prostatic tissue lipidomic profiles shifts after high-dose atorvastatin use in men with prostate cancer.
Raittinen P; Niemistö K; Pennanen E; Syvälä H; Auriola S; Riikonen J; Lehtimäki T; Ilmonen P; Murtola T
Sci Rep; 2020 Jul; 10(1):12016. PubMed ID: 32694638
[TBL] [Abstract][Full Text] [Related]
5. Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the Reduction by Dutasteride of Prostate Cancer Events trial.
Muller RL; Gerber L; Moreira DM; Andriole G; Castro-Santamaria R; Freedland SJ
Eur Urol; 2012 Nov; 62(5):757-64. PubMed ID: 22658758
[TBL] [Abstract][Full Text] [Related]
6. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer.
Nishiyama T; Hashimoto Y; Takahashi K
Clin Cancer Res; 2004 Nov; 10(21):7121-6. PubMed ID: 15534082
[TBL] [Abstract][Full Text] [Related]
7. Profiling adrenal 11β-hydroxyandrostenedione metabolites in prostate cancer cells, tissue and plasma: UPC
du Toit T; Bloem LM; Quanson JL; Ehlers R; Serafin AM; Swart AC
J Steroid Biochem Mol Biol; 2017 Feb; 166():54-67. PubMed ID: 27345701
[TBL] [Abstract][Full Text] [Related]
8. Access and concentrations of atorvastatin in the prostate in men with prostate cancer.
Knuuttila E; Riikonen J; Syvälä H; Auriola S; Murtola TJ
Prostate; 2019 Sep; 79(12):1412-1419. PubMed ID: 31231865
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant Low-dose Statin Use after Radical Prostatectomy: The PRO-STAT Randomized Clinical Trial.
Jeong IG; Lim B; Yun SC; Lim JH; Hong JH; Kim CS
Clin Cancer Res; 2021 Sep; 27(18):5004-5011. PubMed ID: 34011557
[TBL] [Abstract][Full Text] [Related]
10. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase.
Gupta A; Thompson D; Whitehouse A; Collier T; Dahlof B; Poulter N; Collins R; Sever P;
Lancet; 2017 Jun; 389(10088):2473-2481. PubMed ID: 28476288
[TBL] [Abstract][Full Text] [Related]
11. Effects of Preoperative Atorvastatin Treatment On Erectile Function After Radical Prostatectomy: Results From a Subgroup of ESTO1, a Randomized, Double-Blind, Placebo-Controlled Study.
Siltari A; Riikonen J; Fode M; Murtola TJ
J Sex Med; 2019 Oct; 16(10):1597-1605. PubMed ID: 31405764
[TBL] [Abstract][Full Text] [Related]
12. Resveratrol reduces the levels of circulating androgen precursors but has no effect on, testosterone, dihydrotestosterone, PSA levels or prostate volume. A 4-month randomised trial in middle-aged men.
Kjaer TN; Ornstrup MJ; Poulsen MM; Jørgensen JO; Hougaard DM; Cohen AS; Neghabat S; Richelsen B; Pedersen SB
Prostate; 2015 Sep; 75(12):1255-63. PubMed ID: 25939591
[TBL] [Abstract][Full Text] [Related]
13. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer.
Titus MA; Schell MJ; Lih FB; Tomer KB; Mohler JL
Clin Cancer Res; 2005 Jul; 11(13):4653-7. PubMed ID: 16000557
[TBL] [Abstract][Full Text] [Related]
14. Targeted androgen pathway suppression in localized prostate cancer: a pilot study.
Mostaghel EA; Nelson PS; Lange P; Lin DW; Taplin ME; Balk S; Ellis W; Kantoff P; Marck B; Tamae D; Matsumoto AM; True LD; Vessella R; Penning T; Hunter Merrill R; Gulati R; Montgomery B
J Clin Oncol; 2014 Jan; 32(3):229-37. PubMed ID: 24323034
[TBL] [Abstract][Full Text] [Related]
15. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial.
Marks LS; Mazer NA; Mostaghel E; Hess DL; Dorey FJ; Epstein JI; Veltri RW; Makarov DV; Partin AW; Bostwick DG; Macairan ML; Nelson PS
JAMA; 2006 Nov; 296(19):2351-61. PubMed ID: 17105798
[TBL] [Abstract][Full Text] [Related]
16. Sex steroids in serum and prostatic tissue of human cancerous prostate (STERKPROSER trial).
Meunier ME; Neuzillet Y; Raynaud JP; Radulescu C; Ghoneim T; Fiet J; Giton F; Rouanne M; Dreyfus JF; Lebret T; Botto H
Prostate; 2019 Feb; 79(3):272-280. PubMed ID: 30370569
[TBL] [Abstract][Full Text] [Related]
17. Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia.
Habib FK; Ross M; Tate R; Chisholm GD
Clin Endocrinol (Oxf); 1997 Feb; 46(2):137-44. PubMed ID: 9135694
[TBL] [Abstract][Full Text] [Related]
18. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer.
Mostaghel EA; Page ST; Lin DW; Fazli L; Coleman IM; True LD; Knudsen B; Hess DL; Nelson CC; Matsumoto AM; Bremner WJ; Gleave ME; Nelson PS
Cancer Res; 2007 May; 67(10):5033-41. PubMed ID: 17510436
[TBL] [Abstract][Full Text] [Related]
19. Extensive Alteration of Androgen Precursor Levels After Castration in Prostate Cancer Patients and Their Association With Active Androgen Level.
Rouleau M; Neveu B; Caron P; Morin F; Toren P; Lacombe L; Turcotte V; Lévesque É; Guillemette C; Pouliot F
J Urol; 2022 Dec; 208(6):1214-1225. PubMed ID: 36102111
[TBL] [Abstract][Full Text] [Related]
20. Clinical Outcomes and Testosterone Levels Following Continuous Androgen Deprivation in Patients with Relapsing or Locally Advanced Prostate Cancer: A Post Hoc Analysis of the ICELAND Study.
Tombal B; Cornel EB; Persad R; Stari A; Gómez Veiga F; Schulman C
J Urol; 2017 Nov; 198(5):1054-1060. PubMed ID: 28552710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
